Skip to main content
. 2021 Jul 23;4(7):e2117963. doi: 10.1001/jamanetworkopen.2021.17963

Figure 2. Time to Milestone by 2004-2007 vs 2008-2012 Trials.

Figure 2.

The time to various milestones (A, regulatory approval; B, contract execution; C, activation; D, enrollment of first participant; and E, overall start-up) are stratified by early trials from 2004-2007 (Assessment of Pexelizumab in Acute Myocardial Infarction [APEX-AMI], Improved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT], Rivaroxaban vs Warfarin in Nonvalvular Atrial Fibrillation [ROCKET-AF], Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure [ASCEND-AF], and Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome [TRACER]) and contemporary trials from 2008-2012 (Trial Evaluating Cardiovascular Outcomes with Sitagliptin [TECOS], Exenatide Study of Cardiovascular Event Lowering [EXSCEL], Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY], and Examining Use of Ticagrelor in Peripheral Artery Disease [EUCLID]).